Sreekanth K. Chaguturu - 31 Aug 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Sreekanth K. Chaguturu
Issuer symbol
CVS
Transactions as of
31 Aug 2022
Net transactions value
$0
Form type
4
Filing time
02 Sep 2022, 16:50:28 UTC
Previous filing
30 Jun 2022
Next filing
01 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock (RSU) Award $0 +12,735 $0.000000 12,735 31 Aug 2022 Direct F1
holding CVS Common Stock (RSU) 996 31 Aug 2022 Direct F2
holding CVS Common Stock (RSU) 354 31 Aug 2022 Direct F3
holding CVS Common Stock (RSU) 2,154 31 Aug 2022 Direct F4
holding CVS Common Stock (RSU) 1,258 31 Aug 2022 Direct F5
holding CVS Common Stock (RSU) 2,085 31 Aug 2022 Direct F6
holding CVS Common Stock (RSU) 2,776 31 Aug 2022 Direct F7
holding CVS Common Stock (RSU) 6,182 31 Aug 2022 Direct F8
holding CVS Common Stock 2,343 31 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 5,952 31 Aug 2022 Common Stock 5,952 $75.27 Direct F9
holding CVS Stock Option 9,579 31 Aug 2022 Common Stock 9,579 $58.34 Direct F10
holding CVS Stock Option 9,502 31 Aug 2022 Common Stock 9,502 $74.30 Direct F11
holding CVS Stock Option 12,993 31 Aug 2022 Common Stock 12,993 $101.09 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
F2 Consists of Restricted Stock Units (RSUs) awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse on the third anniversary of the grant date.
F3 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
F4 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F5 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F6 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
F7 Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
F8 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
F9 Option became exercisable in four equal annual installments, commencing 11/29/2020.
F10 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F11 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F12 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.